Amyloid β A4 (E737/662) Antibody

1 mg/ml in Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2.

Purification & Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Specificity

Amyloid β A4 (E737) antibody detects endogenous levels of Amyloid β A4 protein.

Applications (Recommended Dilutions)

WB: : 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Storage&Stability

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Background

Proteolytic cleavage of the Amyloid protein precursor (APP) gives rise to the β-Amyloid and Amyloid A4 proteins, which are present in human platelets. Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer’s disease. The Amyloid precursor protein (APP) undergoes alternative splicing, resulting in several isoforms. Proteolytic cleavage of APP leads to the formation of the Amyloid β/A4 Amyloid protein. This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer’s patients. APLP1 (Amyloid precursor-like protein 1) and APLP2 are structurally similar to APP. Human APLP2 is a membrane-bound sperm protein that contains a region highly homologous to the transmembrane-cytoplasmic domains of APP found in brain plaques of Alzheimer’s disease patients.